Chemical Probes Targeting Gliomas with IDH Mutation

针对 IDH 突变神经胶质瘤的化学探针

• 批准号: 8418824
• 负责人: Yongcheng Song
• 金额: $ 34.29万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-30 至 2017-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8418824
• 关键词: Acids; Age; Apoptosis; Autophagocytosis; Binding; Biochemical; Biological; Biological Process; Biological Testing; Brain Neoplasms; Cells; Cellular biology; Cerebrum; Chemicals; Citric Acid Cycle; Complex; Crystallography; Cytosol; DNA Methylation; DNA Sequence; Drug Delivery Systems; Drug Kinetics; Enzymes; Event; Exhibits; Genetic; Germ-Line Mutation; Glioblastoma; Glioma; Growth; Health; High Pressure Liquid Chromatography; Histones; Human; Intervention; Investigation; Isocitrate Dehydrogenase; Isocitrates; Lead; Malignant neoplasm of brain; Measures; Metabolism; Methods; Mitochondria; Molecular Biology; Mus; Mutation; NADP; Neuraxis; Normal Cell; Patients; Pharmaceutical Chemistry; Pharmaceutical Preparations; Play; Primary Neoplasm; Property; Proteins; Quantitative Structure-Activity Relationship; RNA Interference; Research; Risk; Roentgen Rays; Role; Screening procedure; Structure; Structure-Activity Relationship; Testing; Therapeutic; Time; Toxic effect; X-Ray Crystallography; Xenograft Model; Xenograft procedure; absorption; cancer type; clinically relevant; cofactor; counterscreen; cytotoxicity; design; improved; in vitro activity; in vitro testing; in vivo; inhibitor/antagonist; isocitrate; knock-down; mouse model; mutant; neoplastic cell; nervous system disorder; novel; small molecule; tumor initiation; tumorigenesis

DESCRIPTION (provided by applicant): Isocitrate dehydrogenase (IDH) is one of the key enzymes in the tricarboxylic acid cycle, catalyzing the conversion of isocitric acid to ?-ketoglutaric acid (?-KG) using NADP+. DNA sequencing of a large number of human gilomas has revealed that ~75% of low - medium grade gliomas and secondary glioblastoma multiforme (GBM, a highly lethal form of brain tumor) carry IDH mutations, with IDH1 R132H mutation being predominant (~90%). Genetic investigations have found that IDH mutations are always heterozygous, suggesting the wild-type enzyme is essential for both normal and tumor cells, and IDH mutation is an early and critical event in the glioma tumorigenesis. Biochemical characterization of the mutant proteins revealed that they are inactive in converting isocitrate to ?-KG. Rather, all of the mutant proteins, e.g., IDH1(R132H), possess a new enzymatic activity: they catalyze the reduction of ?-KG to D-2-hydroxyglutaric acid (2-HG) using NADPH. This neo-function is responsible for the greatly elevated (>100x) level of 2-HG in primary tumor cells bearing IDH mutations. Growing evidence strongly supports 2-HG is an onco-metabolite and mutant IDH a target for intervention. Although it is clear that a high level of 2-HG is very harmfu to human health (especially central nervous system), whether inhibition of mutant IDH blocks the growth or induces apoptosis of this type of tumor cells remains to be answered. This is because there have been no inhibitors of mutant IDH to date. In addition, RNA interference (RNAi) is not appropriate for this study, since it will also knock down the wild-type IDH enzyme, whose function is essential for both normal and tumor cells. The first Specific Aim is to use medicinal chemistry, protein X-ray crystallography and quantitative structure activity relationship (QSAR) to develop potent and selective inhibitors of IDH1(R132H). The second Specific Aim is to test in vitro biological activities of compounds synthesized in Aim 1 as well as pharmacokinetic and toxicological properties of selected compounds. The third Specific Aim is to determine the in vivo antitumor activity of our potent IDH1(R132H) inhibitors in intra-cerebral xenograft mouse models as well as to use molecular and cell biology methods to identify the mechanisms of action of these novel inhibitors. PUBLIC HEALTH RELEVANCE: Genetic investigations have found the majority (~75%) of human gliomas (a major form of brain cancer) carry mutations of a key enzyme called IDH, which play important roles for the initiation of the tumor. The research proposed is designed to lead to new potential therapeutics to treat this type of cancer.

描述（由申请人提供）：异柠檬酸脱氢酶（IDH）是三羧酸循环中的关键酶之一，催化异柠檬酸转化为？-酮戊二酸（？- KG）。大量人胶质瘤的DNA测序已经揭示，约75%的低-中等级别胶质瘤和继发性多形性胶质母细胞瘤（GBM，一种高致死性形式的脑肿瘤）携带IDH突变，其中IDH 1 R132 H突变占主导地位（约90%）。遗传学研究发现IDH突变总是杂合的，这表明野生型酶对正常细胞和肿瘤细胞都是必需的，IDH突变是胶质瘤发生的早期和关键事件。突变蛋白的生物化学表征揭示了它们在将异柠檬酸转化为 ?- KG.相反，所有的突变蛋白，例如，IDH 1（R132 H）具有新的酶活性：它们催化？- KG转化为D-2-羟基谷氨酸（2-HG）。这种新功能导致携带IDH突变的原发性肿瘤细胞中2-HG水平大大升高（> 100倍）。越来越多的证据强烈支持2-HG是一种致癌代谢物，突变型IDH是干预的靶点。虽然高水平的2-HG对人体健康（尤其是中枢神经系统）的危害是显而易见的，但抑制突变型IDH是否能阻断这类肿瘤细胞的生长或诱导其凋亡仍有待回答。这是因为迄今为止还没有突变IDH的抑制剂。此外，RNA干扰（RNAi）不适合这项研究，因为它也会敲低野生型IDH酶，而野生型IDH酶的功能对正常细胞和肿瘤细胞都是必不可少的。第一个具体目标是利用药物化学、蛋白质X射线晶体学和定量构效关系 （QSAR）开发IDH 1（R132 H）的有效和选择性抑制剂。第二个具体目标是测试目标1中合成的化合物的体外生物活性以及所选化合物的药代动力学和毒理学性质。第三个具体目标是确定我们的有效IDH 1（R132 H）抑制剂在脑内异种移植小鼠模型中的体内抗肿瘤活性，以及使用分子和细胞生物学方法来鉴定这些新型抑制剂的作用机制。 公共卫生相关性：遗传学研究发现，大多数（约75%）人类神经胶质瘤（脑癌的主要形式）携带一种称为IDH的关键酶的突变，该酶在肿瘤的发生中起着重要作用。这项研究旨在寻找治疗这种癌症的新的潜在疗法。